Showing results (471-480 of 561) with videos related to

Sort By:
Pageof 57
International Journal of Hematology|November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trialGrzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Scientific Reports|May 23, 2019
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular SubtypesChanthirika Ragulan, Katherine Eason, Elisa Fontana, et al.
The Lancet. Gastroenterology & Hepatology|June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialTim Meyer, Richard Fox, Yuk Ting Ma, et al.
Leukemia & Lymphoma|November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie HospitalMary Gleeson, Clare Peckitt, David Cunningham, et al.
Eclinicalmedicine|January 9, 2023
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Molecular Cancer Therapeutics|October 18, 2019
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid TumorsFranck Morschhauser, Jean-Pascal Machiels, Gilles Salles, et al.
Gut|May 17, 2019
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesisAlasdair J Scott, James L Alexander, Claire A Merrifield, et al.
The Lancet. Oncology|February 7, 2017
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trialDavid Cunningham, Sally P Stenning, Elizabeth C Smyth, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Pageof 57